FILTER
LATEST INTERVIEWS
Brian Frenzel
CEO, TOSK
Tosk is developing a family of small molecule drugs to prevent the toxic side ef-fects of cancer treatments.
Carlos Ventura
PRESIDENT, BELARUSANGOLA HOLDING LDA
An Angolan company built around partnerships with Belarusian players.
Matthias Vorbeck & Alejandro Gabrielli
GENERAL MANAGER & REGIONAL MANAGER, ANASTACIO OVERSEAS
The company continues expanding in Latin America capitalizing the synergies with the distribution business of Química Anastacio.
Alan Seem
PARTNER, JONES DAY
Jones Day is the largest law firm in the United States and one of the ten largest firms globally.
David Craford
PRESIDENT AND CEO, CYTOBANK
Cytobank is developing and commercializing the leading SaaS platform for machine learning-based analysis of high-complexity life sciences data.
Arturo Bettati
MANAGING DIRECTOR LATIN AMERICA, HALDOR TOPSOE
The Danish company is a world leader in catalysis and process technology.
Olivier Rousset
MARKET MANAGER SPECIAL PARTS, PROFORM
Proform specializes in tube bending, forming, assembling, hydroforming manufacturing and design, for aerospace and defense.
Bernard Lavergne
BERNARD LAVERGNE, PRESIDENT, SN AUVERGNE AERONAUTIQUE
SN Auvergne Aeronautique is expanding its scope, using the synergies created with the Figeac Aero Group.
Franck Picard
OPERATIONAL DIRECTOR, ACNIS INTERNATIONAL
A conversation around the titanium alloy distribution in Europe’s aerospace industry.
Jean-Michel Deck
BUSINESS DEVELOPMENT, COMPOSE
Compose designs and manufactures tools to process thermoplastics and composite materials.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
